Abstract
The mammalian thioredoxin reductases (TrxRs) are a family of selenium-containing pyridine nucleotide disulfide oxidoreductases playing a central role in cellular redox homeostasis and signaling pathways. Recently, these selenoproteins have emerged as promising therapeutic targets for anticancer drug development, often being overexpressed in tumor cells and contributing to drug resistance. Herein, we summarize the current knowledge on metal- and semimetal-containing molecules capable of hampering mammalian TrxRs, with an emphasis on compounds reported in the last decade.
Keywords:
anticancer agents; enzyme inhibitors; metal- and semimetal-based compounds; thioredoxin reductase.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / pharmacology*
-
Auranofin / chemical synthesis
-
Auranofin / pharmacology
-
Aurothioglucose / chemical synthesis
-
Aurothioglucose / pharmacology
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Isoenzymes / antagonists & inhibitors
-
Isoenzymes / chemistry
-
Models, Molecular
-
Neoplasm Proteins / antagonists & inhibitors*
-
Neoplasm Proteins / chemistry
-
Neoplasms / drug therapy
-
Neoplasms / enzymology
-
Neoplasms / pathology
-
Organoplatinum Compounds / chemical synthesis
-
Organoplatinum Compounds / pharmacology
-
Oxidative Stress
-
Phosphines / chemical synthesis
-
Phosphines / pharmacology
-
Ruthenium Compounds / chemical synthesis
-
Ruthenium Compounds / pharmacology
-
Thioredoxin-Disulfide Reductase / antagonists & inhibitors*
-
Thioredoxin-Disulfide Reductase / chemistry
Substances
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Isoenzymes
-
Neoplasm Proteins
-
Organoplatinum Compounds
-
Phosphines
-
Ruthenium Compounds
-
Aurothioglucose
-
Auranofin
-
Thioredoxin-Disulfide Reductase